U.S. govt. inks second deal to buy additional 100M doses of BioNTech-Pfizer COVID-19 vaccine


The new deal opens the door for mass vaccinations in all U.S. states

The New York Times first reported the new details of negotiations between Pfizer and the Trump administration.

The second Pfizer COVID-19 vaccine deal could lead to the vaccination of all Americans.

The newspaper said, “An agreement, which could be announced as early as Wednesday, would help the United States at least partly offset a looming vaccine shortage that could leave as many as 110 million adult Americans uncovered in the first half of 2021.”

Times added that the American pharmaceutical firm began asking for government assistance in acquiring supplies as early as September but was “unhappy about the lack of response.”

Pfizer said in a statement that “we continue to work collaboratively with the U.S. government to get doses of our COVID-19 vaccine to as many Americans as possible. The company is not able to comment on any confidential discussions that may be taking place with the U.S. government.”

On Wednesday, Health and Human Services (HHS) Secretary Alex Azar said, “Securing more doses from Pfizer and BioNTech for delivery in the second quarter of 2021 further expands our supply of doses across the Operation Warp Speed portfolio. This new federal purchase can give Americans even more confidence that we will have enough supply to vaccinate every American who wants it by June 2021.”